SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential rescheduling of marijuana following reports of a planned executive order. The community is discussing the possibility of a major uptrend, potential short squeezes, and analysts updating their target prices. Some traders express caution, pointing to reverse splits and past disappointments.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors digest the company's earnings report and forward guidance, with community sentiment split between bullish expectations for new ATHs and concerns about potential profit-taking. Discussions revolve around the impact of AI chip revenue and gross margins on the stock's valuation. Analyst target price upgrades are anticipated, adding to the bullish outlook for some traders.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading session spurred by an ATM offering announcement after a significant price surge, leading to a community debate on whether it was a 'rug pull'. Traders are discussing the company's fundamentals, potential for a bounce, and comparing it to other high-momentum stocks. The conversation also includes speculation around short squeezes and the company's compliance with listing requirements, all within the context of crypto-related sympathy moves.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors discuss the company's recent Q3 earnings, which included revenue growth and raised guidance, alongside the unexpected announcement of the CEO's departure in 2026. The community is actively debating the impact of these factors, with some anticipating analyst upgrades and a potential rally, while others express concerns about the future direction of the company amid leadership transition. A significant share buyback program has also fueled bullish sentiment, signaling confidence in Lululemon's trajectory.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it showcases its in-house autonomy and AI technology at its first-ever Autonomy and AI Day, with community members discussing the potential impact of new AI-driven features and hardware on the company's future. Investors are weighing Rivian's strategy to develop its own chips and compete with Tesla's autonomous driving capabilities, while some express concerns about the timeline for implementation and the capital expenditure required. There are mixed opinions about the stock's potential, with some anticipating a significant rise and others remain cautious given the company's current financial position.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors await key data and FDA feedback, with anticipation building around potential outcomes for Pemvidutide in MASH and obesity. Bullish community members express confidence in the science and potential buyout scenarios, while bears highlight concerns about trial results and data interpretation. The discussion also includes speculation around competitor data, potential partnership deals, and upcoming announcements.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to a thin-float technical breakout, attracting momentum traders, with the community actively discussing overnight price action and potential for further gains. Community members are also pointing to a recent distribution agreement with Walmart as a longer-term catalyst. Traders are closely watching for offering news.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending amid discussions around immigration enforcement, detention facilities, and the potential impact of government policies. Community perspectives are sharply divided, with some anticipating gains from increased ICE activity and others expressing ethical concerns and criticizing the company's business practices. The conversation also involves potential contract opportunities and the company's financial health.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences ($GLSI) is trending due to anticipation surrounding potential news related to its breast cancer treatment, with speculation focused on the SABCS conference. The community is exhibiting FOMO based on hints of positive data, and some believe shorts may be covering their positions. GLSI is seen as a promising healthcare stock, particularly for women, given its potential for high efficacy.

Frontdoor, Inc. engages in the provision of home service plans. Its home service plans cover the repair or replacement of major home’s systems and appliances. The firm’s service focuses on water heaters, garbage disposals, doorbells, smoke detectors, ceiling fans, central vacuums, refrigerators, dishwashers and trash compactors. Its brands include American Home Shield, HSA, OneGuard and Landmark. The company was founded on January 2, 2018, and is headquartered in Memphis, TN.

Frontdoor Inc.

$FTDR is trending as traders discuss recent trade alerts and potential bullish trends, while noting overbought conditions based on RSI. The community is also evaluating the stock's position relative to its moving averages and key resistance levels like the 60-day high. Overall sentiment appears mixed, balancing short-term profit-taking with longer-term growth potential in the home services sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI

LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.

Best-Performing ETFs of Last Week: Healthcare Rules

Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETF (BBC) Hits New 52-Week High

Biotech ETF BBC just hit a 52-week high on regulatory tailwinds, Fed rate-cut hopes, and cheaper valuations. 

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Trade War or Not, Specific Industry ETFs Are in Sweet Spots

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.

The Zacks Analyst Blog Highlights BWET, GOEX, SLVP, LIT and BBC

BWET, GOEX, SLVP, LIT and BBC topped last week's ETF winners as tech strength, Fed cut hopes and commodity moves drove gains.

Shares of biotech company CureVac N.V. (CVAC) were in the spotlight on Thursday after the company’s fourth-quarter revenue fell below Wall Street estimates.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-business-update/">reported</a> a revenue of €14.5 million ($16.11 million) for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023 and below an analyst estimate of €20.58, according to FinChat data.Revenue for the full year 2024, however, increased by €53.8 million to €535.2 million, exceeding an analyst estimate of €524.17 million. The increase was primarily driven by a new license agreement with GSK, as part of which CureVac received a refundable upfront payment of €400 million.CureVac, however, warned that €480.4 million of the revenue recognized in 2024 must be seen as a positive one-time event that will not be repeated in the future.Pre-tax loss for the fourth quarter came in at €38.6 million, compared to a pre-tax loss of €86.5 million in the same period of 2023.The company said its cash and cash equivalents totaled €481.7 million at the end of December 2024, an increase from €402.5 million at the end of 2023. The company reaffirmed its expected cash runway into 2028.CureVac is developing a new class of medicines based on messenger ribonucleic acid (mRNA). Company CFO Axel Sven Malcomes said that the company’s “robust cash position” provides it with the resources needed to accelerate innovation in its mRNA pipeline.The firm now expects to dose the first patient with its investigational precision immunotherapy CVHNLC, which targets squamous non-small cell lung cancer, in the second half of 2025.On Stocktwits, retail sentiment rose but stayed within ‘neutral’ territory while message volume rose from ‘extremely low’ to ‘low’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_10_at_9_03_56_AM_png_2b72c5e485.webp" alt="CVAC's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 10, 2025 | Source: Stocktwits" width="651" height="151"><figcaption>CVAC's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/CVAC">CVAC shares</a> are down by over 14% year-to-date and by nearly 1% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/futures-traders-cut-down-on-rate-cut-expectations/chfYXsVRbBo">Futures Traders Slash Rate Cut Expectations On Trump’s Tariff Pause, But Here’s What Retail Investors Think</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 Euro= 1.11 USD)

An employee pipettes in a laboratory of the biopharmaceutical company Curevac. Photo: Bernd Weißbrod/dpa (Photo by Bernd Weißbrod/picture alliance via Getty Images)

CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode

The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according to FinChat data.

Equity

ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$40.05
Prev Close	$39.81
Open	$39.88
Dividend Yield	N/A
50-Day Moving Average	$32.70
Beta	N/A
Avg. Volume	19,972.95
PE Ratio	N/A

52-Week High	$40.82
52-Week Low	$13.42
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BBC
ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BBC News

BBCETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF